Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pyxis Oncology, Inc.NASDAQ: PYXS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $19.6M rose 15.0% year over year, behind the +21.5% change in trailing-twelve-month research & development. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Research & development amounted to 531.8% of revenue in FY2025, up 167.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +15.0% toward the trailing-twelve-month pace of +21.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 73.7M USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +9.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.7M | +25.4% |
| FY2024 | 2024-12-31 | 58.75M | +18.5% |
| FY2023 | 2023-12-31 | 49.59M | -42.4% |
| FY2022 | 2022-12-31 | 86.13M | +68.7% |
| FY2021 | 2021-12-31 | 51.05M | — |
Research & Development vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 research & development of $76.25M is the 7th highest of the 10 companies compared; the peer median is $91.32M.
- Its year-over-year change of +21.5% is the 4th highest of 10, against a peer median of -9.4%.
- Research & development amounts to 550.2% of revenue for PYXS, versus a peer median of 596.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| Peer median (excluding PYXS) | $91.32M | -9.4% | +5.1% | 596.9% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | 0 | 0 | 0 | 475K | 2.39M |
| Gross Profit | 0 | 0 | 0 | 15.67M | 11.47M |
| Gross Margin | — | — | — | 97.1% | 82.8% |
| Research & Development | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M |
| Selling, General & Admin | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M |
| Operating Expenses | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| EBITDA | (75.33M) | (120.01M) | (71.86M) | (65.51M) | (73.72M) |
| EBITDA Margin | — | — | — | -405.8% | -532.0% |
| Operating Income | (69.72M) | (123.48M) | (82.2M) | (89.46M) | (84.42M) |
| Operating Margin | — | — | — | -554.1% | -609.2% |
| Interest Income | 23K | 2.76M | 6.63M | 7.04M | 3.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6.26M) | 2.76M | 8.41M | 9.97M | 6.19M |
| Income Before Tax | (75.98M) | (120.72M) | (73.79M) | (79.5M) | (78.24M) |
| Pre-Tax Margin | — | — | — | -492.4% | -564.5% |
| Income Tax Expense | 0 | 0 | 0 | (2.16M) | 1.39M |
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Net Margin | — | — | — | -478.9% | -574.5% |
| EPS (Basic) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| EPS (Diluted) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| Weighted Avg Shares | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
| Weighted Avg Shares (Diluted) | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.